Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | KCNH3 | Q9ULD8 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | PLEC | Q15149 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1533321 | 0.86 | MAPT (0.44) | MAPTRPS6KA2KCNH3ALDH1A1MEN1 | |
| SCHEMBL2064760 | 0.84 | MAPT (0.57) | MAPTRPS6KA2GAAKCNH3ALDH1A1 | |
| SCHEMBL16526575 | 0.82 | RPS6KA2 (0.41) | MAPTRPS6KA2GAAKCNH3ALDH1A1 | |
| SCHEMBL1947326 | 0.80 | MEN1 (0.47) | MAPTGAAALDH1A1MEN1KMT2A | |
| SCHEMBL1950132 | 0.78 | MAPT (0.41) | MAPTGAAALDH1A1 | |
| SCHEMBL3685535 | 0.78 | APP (0.48) | MAPTRPS6KA2GAAALDH1A1MEN1 | |
| SCHEMBL3500535 | 0.78 | APP (0.48) | MAPTGAAALDH1A1MEN1KMT2A | |
| SCHEMBL1947781 | 0.78 | AGER (0.44) | MAPTGAAALDH1A1MEN1KMT2A | |
| SCHEMBL1439847 | 0.78 | MAPT (0.73) | MAPTRPS6KA2GAAALDH1A1MEN1 | |
| SCHEMBL416817 | 0.77 | APP (0.47) | MAPTRPS6KA2GAAKCNH3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024126404-A1 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES | SYNGENTA CROP PROTECTION AG (CH) | 2024-06-20 | — | — | WO | disclosed |
| EP-2373634-B1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MOCHIDA PHARM CO LTD (JP) | 2015-11-11 | — | — | EP | disclosed |
| US-8987242-B2 | Morpholinone compounds as factor IXA inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-03-24 | — | — | US | disclosed |
| US-8642582-B2 | Morpholinone compounds as factor IXa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20110135650-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-06-09 | — | — | US | disclosed |
| US-20110059958-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-03-10 | — | — | US | disclosed |
| CN-1145609-C | Piperazine compounds and medical use thereof | ������ҩ��ʽ���� | 2004-04-14 | — | — | CN | disclosed |
| CN-1281438-A | Piperazine compounds and their use as pharmaceuticals | EFUKU CO LTD (JP) | 2001-01-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110135650-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | SERPINC1, F9, F8 | MAPT 3534/4885RPS6KA2 4465/4885GAA 1405/4885 |
| US-20110059958-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | SERPINC1, F9, F8 | MAPT 3534/4885RPS6KA2 4465/4885GAA 1405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.